Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model

Agmon‐Levin, Nancy; Arango, María‐Teresa; Kivity, Shaye; Katzav, Aviva; Gilburd, Boris; Blank, Miri; Tomer, Nir; Volkov, Alexander; Barshack, Iris; Chapman, Joab; Shoenfeld, Yehuda

doi:10.1016/j.jaut.2014.06.006

Cited by 68 publications

(40 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In (Bourin et al, 2007), whereas other studies have reported increased anxiety levels (Petrik et al, 2007;Agmon-Levin et al, 2014). In sharp contrast, the highest doses of 400 and 800 µg Al/kg did not cause such changes.…”

Section: Discussionmentioning

confidence: 62%

“…In the same way, a neuro-inflammatory/degenerative syndrome has been described in sheep after repeated administrations of alum-containing vaccines (Luján et al, 2013), and impairment of neurocognitive functions and brain gliosis were reported in a murine model of systemic lupus erythematosus-like disease following intramuscular injection of Al hydroxide or vaccine against the hepatitis B virus (Agmon-Levin et al, 2014).…”

Section: Introductionmentioning

confidence: 80%

See 1 more Smart Citation

Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity

et al. 2017

View full text Add to dashboard Cite

Nonlinear dose-response of aluminium hydroxide adjuvant particles: selective low dose neurotoxicity.Toxicology http://dx.doi.org/10.1016/j.tox. 2016.11.018 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. An unusual neuro-toxicological pattern limited to a low dose of Alhydrogel ® was observed.Neurobehavioural changes, including decreased activity levels and altered anxiety-like behaviour, were observed compared to controls in animals exposed to 200 µg Al/kg but not at 400 and 800 µg Al/kg. Consistently, microglial number appeared increased in the ventral forebrain of the 200 µg Al/kg group. Cerebral Al levels were selectively increased in animals exposed to the lowest dose, while muscle granulomas had almost completely disappeared at 6 months in these animals.We conclude that Alhydrogel® injected at low dose in mouse muscle may selectively induce long-term Al cerebral accumulation and neurotoxic effects. To explain this unexpected result, an avenue that could be explored in the future relates to the adjuvant size since the injected suspensions corresponding to the lowest dose, but not to the highest doses, exclusively contained small agglomerates in the bacteria-size range known to favour capture and, presumably, transportation by monocyte-lineage cells. In any event, the view that Alhydrogel® neurotoxicity obeys "the dose makes the poison" rule of classical chemical toxicity appears overly simplistic.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Introductionmentioning

confidence: 80%

Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In another murine model, concomitant exposure to HPV vaccine and pertussis toxin has reportedly resulted in hypothalamic destruction (7). Similarly, exposure to HBV vaccine has been found to accelerate disease progression in a murine model of lupus (8). A number of published papers has also expressed concern regarding the biopersistence and possible neutotoxicity of aluminium-based adjuvants, with some apparent support from animal models (9,10,11).…”

Section: Vaccination-induced Autoimmunity: Potential Mechanismsmentioning

confidence: 99%

Vaccination and Autoimmune Phenomena

Janković

2017

CEJP

View full text Add to dashboard Cite

“…In addition, hepatitis B vaccination has been implicated as a potential trigger for the occurrence or exacerbation of lupus (Aron-Maor and Shoenfeld 2001;Geier and Geier 2004;Millet et al 2009). Moreover, in a murine model, immunization with hepatitis B vaccine induced the acceleration of kidney disease with the elevation of anti-dsDNA antibodies in lupus-prone mice (Agmon-Levin et al 2014). On the other hand, small-sized prospective studies demonstrated that hepatitis B vaccination was safe in inactive juvenile and adult patients with SLE and that the antibody response was not affected by immunosuppressive therapy (Kuruma et al 2007;Aytac et al 2011).…”

Section: Hepatitis B Vaccination In Lupus Patientsmentioning

confidence: 99%

Pretreatment Screening for Hepatitis B Virus Infection in Patients with Systemic Lupus Erythematosus

Watanabe

Ishii

Harigae

2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is one of the most common diseases, and approximately two billion people are infected with HBV in the world. Until recently, hepatitis B surface antigen (HBsAg)-negative patients, carrying hepatitis B surface antibody (anti-HBs) and/or hepatitis B core antibody (anti-HBc), have been considered to have achieved the resolution of HBV infection; however, among those patients, the reactivation of HBV has been increasingly reported after chemotherapy, hematopoietic stem cell transplantation, or immunosuppressive therapy. The reactivation of HBV can cause lethal hepatitis called de novo hepatitis B. Therefore, serological examination for HBV infection before starting immunosuppressive therapy is now recommended for all patients with rheumatic diseases. Systemic lupus erythematosus (SLE) is one of the autoimmune diseases characterized by the production of autoantibodies and usually requires immunosuppressive therapy. However, to date, a few reports are available regarding the prevalence and time course of HBV infection in patients with SLE under immunosuppressive therapy. In this review, we update the prevalence and time course of HBV infection in lupus patients using our data and previous papers available, with a special emphasis on occult HBV infection and a decrease of HBV-related antibodies (anti-HBs and anti-HBc) under immunosuppressive therapy. This review also highlights the screening and management of HBV infection currently recommended and the potential role of HBV infection in the pathogenesis of SLE. Throughout the present review, we recommend the pretreatment screening for HBV infection in patients with SLE as well as patients with other rheumatic diseases.

show abstract

Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model

Cited by 68 publications

References 91 publications

Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity

Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity

Vaccination and Autoimmune Phenomena

Pretreatment Screening for Hepatitis B Virus Infection in Patients with Systemic Lupus Erythematosus

Contact Info

Product

Resources

About